UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 15, 2004
KINDRED HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-14057 | 61-1323993 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(IRS Employer Identification No.) |
680 South Fourth Street
Louisville, Kentucky
(Address of principal executive offices)
40202-2412
(Zip Code)
Registrant’s telephone number, including area code: (502) 596-7300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
| r | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| r | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| r | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| r | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.01 (d)
Kindred Healthcare, Inc. (the “Company”) has announced that the New York Stock Exchange (“NYSE”) has approved the Company’s common stock for listing on the NYSE, and that the Company filed its initial listing application with the NYSE on September 15, 2004. The Company anticipates that trading in its common stock on the NYSE will begin on October 28, 2004 under the ticker symbol “KND.”
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01.
| (c) | Exhibits |
Exhibit 99.1 Press Release dated September 15, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.
| Date: September 16, 2004 |
By: | /s/ Joseph L. Landenwich | ||||||
| Joseph L. Landenwich Senior Vice President of Corporate Legal Affairs and Corporate Secretary | ||||||||